The integration, which quietly debuted in December 2024 (as if it were a shy debutante at a ball), allows UK and EEA customers to send USDC, USDT, and POL with the speed of a Cossack’s horse and the cost of a single samovar’s worth of tea. The result? Over $690 million in transactions, proving that sometimes, silence speaks louder than words. 🤫💸
Ah, the marvels of the modern world! Grab, the super-app so grand it makes other apps look like mere crumbs, has joined forces with StraitsX, a stablecoin sorcerer from the land of Singapore. Together, they plot to weave a Web3 payments system so slick, it’ll make traditional banking look like a snail on a Sunday stroll. 🐌
The timing and the scale have raised urgent questions about political responsibility, judicial oversight, and the fate of funds tied to one of Argentina’s most contentious crypto investigations. 🧠
According to a November 14, 2025 SEC filing, 5AM Venture Management, LLC, liquidated its position in Viking Therapeutics (VKTX 0.68%) as of Q3 2025. The fund sold its entire holding of 189,593 shares over the quarter, reducing its stake from 1.9% of assets under management to zero. The estimated value of the transaction was approximately $5.02 million based on the average share price for the quarter.
Lo, Standard Chartered’s Geoffrey Kendrick, that most patient of sages, beholds the carnage of Tuesday’s midnight plunge and chuckles, as if witnessing the third act of a divine comedy. “Behold!” he proclaims to his clients, “this sell-off is but a familiar specter, a ghost from the past two years, haunting us with its predictable wails!”
According to a filing with the SEC, the fund liquidated 282,313 shares, a calculated retreat from a venture that had grown increasingly elusive. The average share price for the quarter, now a mere shadow of its former self, rendered the trade’s value at $13,325,174. One might call it a rational decision, though the word “rational” sits uneasily in the presence of hope.
Both digital darlings are wobbling on their tightropes, testing crucial support levels after a market-wide tumble that left everyone’s knickers in a twist. 🎢
On November 14, 2025, Bain Capital Life Sciences Investors, LLC offloaded 122,106 shares of Pharvaris. The post-sale holding is now 3,181,275 shares, valued at $79.37 million. A quarter-over-quarter increase, mind you, despite the sale. It’s like buying a coffee, then selling it for a bit more-only with stock. My brain hurts just thinking about it.
The filing with the Securities and Exchange Commission, that most solemn of rituals, reveals the fund’s fourteenth disclosed position in Wingstop, a stake accounting for 4.45% of its U.S. equity holdings. One might wonder: what forces conspire to draw such a behemoth of capital toward a company whose stock has languished, descending 29% over the past year, its price a shadow of its former self? Is it the siren song of a discounted valuation, or the delusion of a “buy the dip” mantra, a gambit as perilous as it is common?
It appears that the US government, perhaps bored with routine oversight, recently shifted a modest $23,000 worth of WIN tokens on the Tron network. These tokens, snatched from the notorious Alameda Research two years prior, are now on the move, reminding all that even small sparks can ignite wildfires of speculation. 🚒🔥